Janssen to pledge COVID-19 vaccine to African Union
Johnson & Johnson subsidiary Janssen Pharmaceutica NV has confirmed to deliver 220 million doses of its COVID-19 vaccine to the African Vaccine Acquisition Trust (AVAT).
Bispecific IgG switch off SARS-CoV-2 escape variants
A bispecific antibody designed by a Swiss-Czech research team suppressed viral escape of SARS-CoV-2 variants in animals.
Step Pharma SAS raises 35m in Series B
Kurma Partners-founded Step Pharma has baged 35m in a Series B financing to advance its blood cancer lead STP938.
AZD1222 claims 79% effecacy in pivotal US study
Following assemingly good results in a Phase III study AstraZeneca goes for Emergency Use Approval in the US.
EMA recommends to continue AZD1222 vaccinations
On Tuesday, Emer Cooke had already hinted at it. Now the EMA’s PRAC committee confirmed: the benefits of AZ1222 by far outweigh the risks of the COVID-19 vaccine.
Novel COVID antibody enters clinical testing
German CORAT Therapeutics GmbH got the greenlight for Phase Ib/II testing of COR-101, an antibody that reduced virus load in the lung by more than 99 % within three days.
B.1.1.7 variant associated with higher mortality
The B.1.1.7 variant of SARS-CoV-2, which was first identified in the UK, may be associated with an increased risk of death, a Nature study suggests.
Roche in take-over deal with GenMark Diagnostics
Roche to acquire GenMark Diagnostics, Inc., to access platform to test for broad range of pathogens with one patient sample.
Media hype on Denmarks decision to halt AZD1222 vaccination
While media reports suggest AstraZenecas COVID-19 jab might have caused blot clots, the EMA didn’t confirm a causal relationship.
Roche Phase III study misses COVID-19 endpoint
Swiss Roche AG has missed the primary endpoint in the REMDACTA trial in patients with severe COVID-19 pneumonia.